New York Life Investment Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

New York Life Investment Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,245	Closed	-$572K	–	1338
2023 Q4	$572K	Sell	9,245 -235	-2%	-$12.3K	0.01%	784
2023 Q3	$436K	Sell	9,480 -1,510	-14%	-$82.4K	﹤0.01%	817
2023 Q2	$632K	Sell	10,990 -1,591	-13%	-$70.5K	0.01%	636
2023 Q1	$472K	Sell	12,581 -3,180	-20%	-$104K	0.01%	1059
2022 Q4	$442K	Buy	15,761 +1,741	+12%	+$50.6K	0.01%	1004
2022 Q3	$394K	Buy	14,020 +1,030	+8%	+$33.6K	﹤0.01%	958
2022 Q2	$452K	Buy	+12,990	New	+$464K	0.01%	783

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

New York Life Investment Management's AMPH Position: Q1 2024 in Review

New York Life Investment Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 9,245 shares — an estimated $572K sold.

New York Life Investment Management first reported a position in AMPH in Q2 2022 and held it in 7 quarters. The position peaked at $632K in Q2 2023. 271 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

New York Life Investment Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
New York Life Investment Management sold 9,245 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $572K.
New York Life Investment Management first reported a position in Amphastar Pharmaceuticals in Q2 2022 and held it in 7 quarters.
New York Life Investment Management's Amphastar Pharmaceuticals position peaked at $632K in Q2 2023.
271 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.